PL-3994 for Acute Severe Asthma
PL-3994, discovered and developed by scientists at Palatin Technologies, is a natriuretic peptide receptor A (NPRA) agonist compound. Developed initially for the treatment of congestive heart failure (CHF), PL-3994 has successfully completed both a Phase 1 and Phase 2a trial.
NPRA agonist compounds have demonstrated utility in relaxing smooth muscle in airways. Published data supports this bronchodilator activity with both intravenous and aerosol NPRA agonist compounds. Palatin Technologies is exploring use of PL-3994 for treatment of acute severe asthma, particularly for use in patients not adequately treated by beta 2 agonists, such as albuterol rescue inhalers. Acute severe asthma, particularly beta 2 agonist refractory asthma, is an area of high unmet medical need.
PL-3994 is a synthetic molecule, incorporating a novel and proprietary amino acid mimetic developed by Palatin Technologies. PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug with improved pharmacokinetic and pharmacodynamic properties.
|
